Idiopathic Type 1 Diabetes in Dallas, Texas

A 5-year experience

  1. Antonio Piñero-Piloña, MD,
  2. Patrick Litonjua, MD,
  3. Larissa Aviles-Santa, MD and
  4. Philip Raskin, MD
  1. Department of Internal Medicine, University of Texas Southwestern Medical School, Dallas, Texas

    Abstract

    OBJECTIVE—To describe the clinical course of individuals with idiopathic type 1 diabetes after a mean of 5 years from diagnosis and to compare glycemic control between those treated with diet and/or oral agents and those treated with insulin at follow-up.

    RESEARCH DESIGN AND METHODS—Medical records of patients with new-onset diabetes, who presented with unprovoked diabetic ketoacidosis, were reviewed. A total of 54 of these individuals were traceable and had relevant data collected within the past 2 years. All patients had nonsusceptibility HLA haplotypes and no serological evidence of autoimmune type 1 diabetes. Most of these patients were male (41 men and 13 women), were non-Caucasian, were obese at the time of diagnosis (BMI 31.6 ± 6.3 kg/m2), reported weight loss (12.8 ± 9.8 kg), had a family history of type 2 diabetes, and had acanthosis nigricans. At follow-up, 33 patients were still taking insulin and 21 were on diet and/or oral-agent therapy.

    RESULTS—Both treatment groups were similar in clinical presentation and demographics at diagnosis. After 4.8 ± 1.6 years of follow-up, the 33 patients that were receiving insulin had a lower HbA1c than the 21 patients who were using therapies other than insulin (7.8 ± 2.4 vs. 11.1 ± 3.5%, P = 0.009; 95% CI 1.0–6.5%). There was a high correlation between change in weight and change in HbA1c at follow-up (r = 0.45, P < 0.001, n = 54). There were no differences in the rate of diabetes complications or in the episodes of recurrent diabetic ketoacidosis.

    CONCLUSIONS—Idiopathic type 1 diabetes occurs more frequently in male African-American patients but also occurs in other ethnic groups. Patients with idiopathic type 1 diabetes who continued to use insulin had better glycemic control than patients using therapies other than insulin. Regained weight is a good clinical marker for improvement in glycemic control. Individuals with this type of diabetes should not be switched to therapies other than insulin.

    Footnotes

    • Address correspondence and reprint requests to Dr. Philip Raskin, University of Texas Southwestern Medical School, Department of Internal Medicine, 5323 Harry Hines Blvd. G5.238, Dallas, TX 75390. Mail Code 8858. E-mail: philip.raskin{at}utsouthwestern.edu.

      Received for publication 26 December 2000 and accepted in revised form 6 March 2001.

      P.R. is a member of the Scientific Advisory Boards for Novo Nordisk and Takeda Pharmaceuticals and has received honoraria and grants from Eli Lily, Novo Nordisk, Pfizer, SmithKline Beecham, and Takeda pharmaceuticals.

      A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

    « Previous | Next Article »Table of Contents